Subcutaneous Solutions: The Evolving Landscape of Drug Administration in Multiple Myeloma Care

Videos

Innovations in Administration—Spotlight on On-Body Injectors

08/18/2025

Sikander Ailawadhi, MD; Joseph Mikhael, MD, MEd, FRCPC; Beth Faiman, CNP, PhD

Drs Ailawadhi, Mikhael, and Faiman discuss the evolving landscape of subcutaneous administration and on-body injector innovation in multiple myeloma.

Drs Ailawadhi, Mikhael, and...

08/18/2025

Oncology

Videos

Deep Dive—On-Body Injectors vs Intravenous Administration

08/18/2025

Sikander Ailawadhi, MD; Joseph Mikhael, MD, MEd, FRCPC; Beth Faiman, CNP, PhD

Expert oncologists discuss subcutaneous on-body injection vs intravenous administration during multiple myeloma treatment through the lens of the phase 3 IRAKLIA trial.

Expert oncologists discuss...

08/18/2025

Oncology

Videos

Deep Dive—On-Body Injectors vs Traditional Subcutaneous Administration

08/18/2025

Sikander Ailawadhi, MD; Joseph Mikhael, MD, MEd, FRCPC; Beth Faiman, CNP, PhD

View an in-depth discussion on subcutaneous on-body injection vs traditional push subcutaneous administration during multiple myeloma treatment through the lens of the phase 2 IZALCO trials.

View an in-depth discussion on...

08/18/2025

Oncology

Videos

Isatuximab-irfc in the Multiple Myeloma Landscape

08/18/2025

Sikander Ailawadhi, MD; Joseph Mikhael, MD, MEd, FRCPC; Beth Faiman, CNP, PhD

Review the role and relevance of isatuximab-irfc in the multiple myeloma landscape today.

Review the role and relevance of...

08/18/2025

Oncology

Videos

Integrating the Evidence—The Role of On-Body Injectors in Evolving Multiple Myeloma Care

08/18/2025

Sikander Ailawadhi, MD; Joseph Mikhael, MD, MEd, FRCPC; Beth Faiman, CNP, PhD

Explore the broader impact of on-body injection delivery on patient care and practice logistics for patients with multiple myeloma, and review data from the IRAKLIA and IZALCO trials.

Explore the broader impact of...

08/18/2025

Oncology

Videos

Final Thoughts on On-Body Injectors

09/16/2025

Paul G. Richardson

Dr Paul Richardson reflects on discussions surrounding the use of on-body injectors in multiple myeloma treatment.

Dr Paul Richardson reflects on...

09/16/2025

Oncology

Recent News

FDA Approval

FDA Approves Vepdegestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

05/01/2026

Emily Estrada

Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

Based on results from the phase...

05/01/2026

Oncology

News

Varegacestat Advances Toward FDA Review in Desmoid Tumors

04/30/2026

Stephanie Holland

Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.

Based on results from the phase...

04/30/2026

Oncology

News

Nirogacestat Improves Outcomes Across Prognostic Subgroups of Patients With Desmoid Tumors

04/30/2026

Stephanie Holland

Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.

Results from a post hoc analysis...

04/30/2026

Oncology

News

FOG-001 Shows Early Activity in Patients With Desmoid Tumors

04/30/2026

Stephanie Holland

Results from a phase 1/2 study demonstrate that FOG-001 shows early clinical activity with manageable safety in patients with desmoid tumors.

Results from a phase 1/2 study...

04/30/2026

Oncology

News

Bireociclib Plus Fulvestrant in HR-Positive, HER2-Negative Advanced Breast Cancer

04/30/2026

Emily Estrada

Final results from the phase 3 BRIGHT-2 trial demonstrated that bireociclib plus fulvestrant significantly improves PFS compared with fulvestrant alone in previously treated HR-positive, HER2-negative advanced breast cancer.

Final results from the phase 3...

04/30/2026

Oncology

News

Romiplostim Reduces the Need for Dose Modifications in Chemotherapy-Induced Thrombocytopenia

04/30/2026

Emily Estrada

Results from the phase 3 RECITE trial demonstrated that romiplostim significantly reduced the need for chemotherapy dose modifications in patients with chemotherapy-induced thrombocytopenia.

Results from the phase 3 RECITE...

04/30/2026

Oncology

News

Tri-Weekly Cisplatin Matches Weekly Dosing With Better Tolerability in Cervical Cancer

04/30/2026

Stephanie Holland

Results from the phase 3 TACO trial demonstrate that tri-weekly cisplatin provides similar survival with improved safety and quality of life vs weekly dosing in patients with locally advanced cervical cancer.

Results from the phase 3 TACO...

04/30/2026

Oncology

FDA Alerts

FDA Grants Breakthrough Therapy Designation to TERN-701 in Ph-Positive Chronic Myeloid Leukemia

04/30/2026

Stephanie Holland

Based on data from the phase 1/2 CARDINAL study, the FDA has granted breakthrough therapy designation to TERN-701 for previously treated Ph-positive chronic myeloid leukemia.

Based on data from the phase 1/2...

04/30/2026

Oncology

News

HSK42360 Shows Clinical Promise in BRAF V600-Mutant Glioma

04/29/2026

Emily Estrada

Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.

Results from a phase 1 study...

04/29/2026

Oncology

News

G-CSF Supports Effective Docetaxel Delivery in Metastatic Hormone-Sensitive Prostate Cancer

04/29/2026

Emily Estrada

Post hoc analysis results from the phase 3 ARASENS trial demonstrate that early G-CSF use and appropriate dose modifications allow most patients with metastatic hormone-sensitive prostate cancer to maintain effective docetaxel dosing with...

Post hoc analysis results from...

04/29/2026

Oncology